C Mestayer1, M Blanchère, F Jaubert, B Dufour, I Mowszowicz. 1. Laboratoire de Recherche sur la Physiologie et la Pathologie Gonadique, Service d'Endocrinologie et Médecine de la Reproduction, Faculté de médecine Necker-Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France.
Abstract
BACKGROUND: In prostate cancer cell lines, androgen receptor (AR) coactivators modulate the transcriptional activity of AR. However, very little is known about their expression in normal prostate tissue and during progression to cancer. METHODS: AR and coactivators ARA54, ARA55, ARA70, and SRC1 RNA were analyzed by RT-PCR in normal and tumoral tissues of the same prostate, in prostate cell lines, and after hormonal treatments of prostate epithelial cells. RESULTS: AR-coactivators were expressed in normal and tumoral tissues and in cultured prostate cells; only ARA55 expression was decreased in tumoral relative to normal tissue of all seven prostates analyzed. It was not expressed in LNCaP and DU145 cancer cells and low in PNT2 immortalized cells in which all coactivator's expression were down regulated by DHT and up regulated by E2. In addition, coactivator's expression was increased in hyperplastic relative to normal prostate fibroblasts. CONCLUSIONS: ARA55 is both an AR coactivator and a focal adhesion protein (Hic-5). Its role in the progression of prostate carcinoma may therefore involve these two different functions. Its decrease in cancer tissue suggests that it plays a different role than that expected, namely, facilitate cell proliferation and therefore mobility and metastasis. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: In prostate cancer cell lines, androgen receptor (AR) coactivators modulate the transcriptional activity of AR. However, very little is known about their expression in normal prostate tissue and during progression to cancer. METHODS:AR and coactivators ARA54, ARA55, ARA70, and SRC1 RNA were analyzed by RT-PCR in normal and tumoral tissues of the same prostate, in prostate cell lines, and after hormonal treatments of prostate epithelial cells. RESULTS:AR-coactivators were expressed in normal and tumoral tissues and in cultured prostate cells; only ARA55 expression was decreased in tumoral relative to normal tissue of all seven prostates analyzed. It was not expressed in LNCaP and DU145 cancer cells and low in PNT2 immortalized cells in which all coactivator's expression were down regulated by DHT and up regulated by E2. In addition, coactivator's expression was increased in hyperplastic relative to normal prostate fibroblasts. CONCLUSIONS:ARA55 is both an AR coactivator and a focal adhesion protein (Hic-5). Its role in the progression of prostate carcinoma may therefore involve these two different functions. Its decrease in cancer tissue suggests that it plays a different role than that expected, namely, facilitate cell proliferation and therefore mobility and metastasis. Copyright 2003 Wiley-Liss, Inc.
Authors: Stavit Drori; Geoffrey D Girnun; Liqiang Tou; Jeffrey D Szwaya; Elisabetta Mueller; Kai Xia; Xia Kia; Ramesh A Shivdasani; Bruce M Spiegelman Journal: Genes Dev Date: 2005-02-01 Impact factor: 11.361
Authors: Silke Kaulfuss; Michal Grzmil; Bernhard Hemmerlein; Paul Thelen; Stefan Schweyer; Jürgen Neesen; Lukas Bubendorf; Andrew G Glass; Hubertus Jarry; Bernd Auber; Peter Burfeind Journal: Mol Endocrinol Date: 2008-05-01
Authors: Liesel M FitzGerald; Xiaotun Zhang; Suzanne Kolb; Erika M Kwon; Ying Ching Liew; Antonio Hurtado-Coll; Beatrice S Knudsen; Elaine A Ostrander; Janet L Stanford Journal: Hum Mutat Date: 2012-10-04 Impact factor: 4.878